

Presentation Number	Author Name & Surname	Institution	Country	Poster Title	Session	Date	Time	Room
OP-1	Tatiana Mushkarina	National Medical Research Radiological Center of the Ministry of Health of the Russian Federation	RUSSIA	REGULATORY T CELLS IN PERIPHERAL BLOOD AND BONE MARROW IN PATIENTS WITH B-CELL LYMPHOPROLIFERATIVE DISEASES	ORAL PRESENTATIONS SESSION I	9 October 2023	07.30 - 08.15	1
OP-2	Barbaros Şahin Karagün	Faculty of Medicine, Acıbadem University, Adana Hospital	TURKEY	THE PROPHYLAXIS AND THE TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE AFTER PEDIATRIC HEMATOPOETIC STEM CELL TRANSPLANTATION: OUR SINGLE CENTRE EXPERIENCE	ORAL PRESENTATIONS SESSION I	9 October 2023	07.30 - 08.15	1
OP-3	Panayotis Kaloyannidis	King Faisal Specialist Hospital & Research Centre	SAUDI ARABIA	IS THERE ANY IMPACT OF URIC ACID LEVELS DURING THE PERI-TRANSPLANT PERIOD ON ACUTE GRAFT VS. DISEASE INCIDENCE AND ALLOTRANSPLANT OUTCOME?	BEST SELECTED ORAL PRESENTATIONS SESSION	9 October 2029	14.30 - 14.40	MAIN HALL
OP-4	Fulya ipek	Hacettepe University	TURKEY	RELATION BETWEEN FATIGUE AND QUALITY OF LIFE IN CANCER PATIENTS RECEIVING OUTPATIENT CHEMOTHERAPY	ORAL PRESENTATIONS SESSION I	9 October 2023	07.30 - 08.15	1
OP-5	Mona Hassanein	King Faisal Specialist Hospital & Research Centre	SAUDI ARABIA	SECONDARY AML PATIENTS WITH POOR RISK CYTOGENETICS HAVE A HIGH RISK OF DEATH POST ALLOGENEIC STEM CELL TRANSPLANTATION IN ABSENCE OF CHRONIC GVHD	ORAL PRESENTATIONS SESSION I	9 October 2023	07.30 - 08.15	1
OP-6	Anna Sergeeva	National Research Center for Hematology	RUSSIA	CHARACTERIZATION OF MAPK SIGNALING PATHWAY IN NEWLY DIAGNOSED MULTIPLE MYELOMA.	ORAL PRESENTATIONS SESSION I	9 October 2023	07.30 - 08.15	1
OP-7	Ali Zahit Bolaman	School of Medicine, Adnan Menderes University	TURKEY	ORIGINAL VERSUS GENERIC LENALIDOMIDE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: COMPARISON OF EFFECTIVITY AND ADVERSE EVENTS	ORAL PRESENTATIONS SESSION I	9 October 2031	07.30 - 08.15	2
OP-8	Gozde Akin Kağızcanlı	Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital	TURKEY	THE EFFICACY AND SAFETY OF GRANULOCYTE TRANSFUSION IN PEDIATRIC NEUTROPENIC PATIENTS	ORAL PRESENTATIONS SESSION I	9 October 2031	07.30 - 08.15	2
OP-9	Vidmante Dayildite	N. N. Blokhin National Cancer Research Center of the Ministry of Health of Russian Federation	RUSSIA	THIOTEPA-BASED CONDITIONING AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN CHILDREN WITH HIGH-RISK MEDULLOBLASTOMA.	ORAL PRESENTATIONS SESSION I	9 October 2031	07.30 - 08.15	2
OP-10	Sevgi Kalayoğlu Beşikçi	Istanbul Faculty of Medicine, Istanbul University	TURKEY	ROLE OF [8GA]PENTIXAFOR-PET/CT AS A NOVEL IMAGING OF CXCR4 EXPRESSION IN MULTIPLE MYELOMA; COMPARISON TO [18F]FDG-PET/CT	ORAL PRESENTATIONS SESSION I	9 October 2031	07.30 - 08.15	2
OP-11	Fidan Khalilova	Institute of Hematology and Transfusiology	AZERBAIJAN	MODERN APPROACHES TO DIAGNOSIS AND TREATMENT OF VARIOUS CLINICAL FORMS OF POLYCYTHEMIA VERA.	ORAL PRESENTATIONS SESSION I	9 October 2031	07.30 - 08.15	2
OP-12	Gunay Aliyeva	Institute of Hematology and Transfusiology	AZERBAIJAN	SPECTRUM AND GEOGRAPHICAL DISTRIBUTION OF B-THALASSEMIA MUTATIONS IN AZERBAIJAN	ORAL PRESENTATIONS SESSION I	9 October 2035	07.30 - 08.15	3
OP-13	Svetlana Chulkova	N. N. Blokhin National Cancer Research Center of the Ministry of Health of Russian Federation	RUSSIA	Cancer Stem Cells (CSCs)	ORAL PRESENTATIONS SESSION I	9 October 2035	07.30 - 08.15	3
OP-14	Melih Simsek	Yozgat City Hospital	TURKEY	SINGLE INSTITUTION EXPERIENCE OF THYMOMA AND THYMIC CARCINOMA PATIENTS	ORAL PRESENTATIONS SESSION I	9 October 2035	07.30 - 08.15	3
OP-15	Iulia Miroliubova	Institute of Hematology, Almazov National Medical Research Centre	RUSSIA	ANALYSIS OF THE PROGRESSION-FREE SURVIVAL OF CLL PATIENTS WHO RECEIVED FIRST-LINE BENDAMUSTINE-RITUXIMAB THERAPY DEPENDING ON THE ELIMINATION RATE OF THE MINIMUM RESIDUAL DISEASE AND MUTATIONAL STATUS IGHV GENES	BEST SELECTED ORAL PRESENTATIONS SESSION	9 October 2028	13.50 - 14.00	MAIN HALL
OP-16	Ghaleb Elyamany	Prince Sultan Military Medical City (PSMMC)	SAUDI ARABIA	PROGNOSTIC IMPLICATION OF NOTCH 1 EXPRESSION AMONG ADULT PATIENTS WITH NORMAL CYTOGENETIC ACUTE MYELOID LEUKAEMIA	BEST SELECTED ORAL PRESENTATIONS SESSION	9 October 2021	14.00 - 14.10	MAIN HALL
OP-17	Salwa Bakr	Fayoum University	EGYPT	GENETIC VARIATIONS IN TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR 1 (TRAIL-R1) GENE AND THE SUSCEPTIBILITY TO B CELL NON-HODGKIN LYMPHOMA IN EGYPT	ORAL PRESENTATIONS SESSION I	9 October 2035	07.30 - 08.15	3
OP-18	Omer Ekinçi	Faculty of Medicine, Firat University	TURKEY	PEGYLATED INTERFERON ALFA-2A IS EFFECTIVE AND DECREASES LDH LEVELS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA	ORAL PRESENTATIONS SESSION I	9 October 2035	07.30 - 08.15	3